Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes

Journal of Hypertension
K NagataY Maruyama

Abstract

To clarify the pathophysiological significance of the renin-angiotensin system (RAS) in monocytes, we examined the effect of its blockade on tissue factor and plasminogen activator inhibitor-1 (PAI-1) synthesis in human cultured monocytes. Monocytes were isolated from healthy volunteers and cultured. Tissue factor and PAI-1 antigens in culture medium and cells were measured by enzyme-linked immunosorbent assay and Western blotting, and mRNA levels were assessed by reverse-transcriptase polymerase chain reaction. We show that the RAS is present in isolated human peripheral blood monocytes. Exogenous angiotensin II increased the levels of tissue factor antigen and mRNA in cultured monocytes, but not of PAI-1 synthesis. An angiotensin converting enzyme (ACE) inhibitor (captopril) and an angiotensin II type 1 (AT1) receptor antagonist (candesartan) decreased the levels of tissue factor protein and mRNA in cultured monocytes. These alterations were accompanied by a reduction in the levels of tumour necrosis factor-alpha protein and mRNA. The levels of PAI-1 protein were reduced by captopril, but not by candesartan. A bradykinin B2 receptor antagonist abolished the suppressive effect of captopril on PAI-1 antigen. An ACE inhibitor an...Continue Reading

References

Aug 1, 1979·Japanese Circulation Journal·H KobayashiM Miyahara
Jan 23, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Jul 1, 1985·The Histochemical Journal·M G WhiteJ M Anderson
Jun 27, 1994·FEBS Letters·A W HahnT J Resink
Nov 3, 1995·The Journal of Biological Chemistry·A BierhausJ Greten
Nov 1, 1995·The Journal of Clinical Investigation·D M KerinsD E Vaughan
Jun 1, 1995·Circulation·P Libby
Jan 14, 1999·The New England Journal of Medicine·R Ross
Nov 26, 1999·Journal of Cellular Biochemistry·S I BriandG Guillemette
Jul 25, 2000·Circulation Research·A D SchecterM B Taubman

❮ Previous
Next ❯

Citations

Jun 6, 2002·Atherosclerosis·Kenji NagataYukio Maruyama
Nov 5, 2002·Journal of Clinical Pharmacology·James P TsikourisGary E Meyerrose
May 8, 2003·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Shinji MorimotoTadaaki Iwasaki
May 16, 2002·Drugs·Stephanie E Easthope, Blair Jarvis
Apr 10, 2010·Journal of Atherosclerosis and Thrombosis·Masashi KamiokaYasuchika Takeishi
Jun 16, 2009·Clinica Chimica Acta; International Journal of Clinical Chemistry·Maria Adriana SardoAntonino Saitta
Jun 17, 2004·British Journal of Haematology·William B StrawnCarlos M Ferrario
May 20, 2009·Journal of Cellular Physiology·Nobuo SakamotoYasuchika Takeishi
Sep 12, 2002·Expert Opinion on Therapeutic Targets·Donald S Houston
Aug 28, 2010·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Alessandra Del FiorentinoRoberto Pedrinelli
Jul 16, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Takayuki SakamotoYukio Maruyama
Apr 15, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Toshiyuki IshibashiYukio Maruyama
Jun 10, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Alvin H Schmaier
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Patrick G ArndtG Scott Worthen
Jan 10, 2020·Fukushima Journal of Medical Science·Hironori UekitaTakeishi Yasuchika
Jan 11, 2005·The Journal of Biological Chemistry·Hiroshi OhkawaraYukio Maruyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.